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Introduction
Galen (AD133–200) was the ﬁrst to use the term
psoriasis, which comes from the Greek word “psora”,
meaning itch. Although psoriasis may cause irritation,
this symptom is not one of the characteristic features
of the disease.
Epidemiology
Psoriasis is most common in the northern European
countries, with an incidence of 2.9% in Denmark and
2.8% in the Faroe Isles. The average incidence in
European countries is given as 2% and is slightly lower
in the USA, being 1.5%. In the Middle Eastern Arab
states, a similar incidence to the European countries,
i.e. of 2%, has been found. In the far east, an incidence
of 0.37% has been reported in China. The incidence
in the Indian subcontinent has been reported as
similar to Europeans in some studies, whilst in others,
it is lower and similar to the Chinese. There is a higher
incidence in East Africans compared to those from
West Africa. Psoriasis is said to be non-existent in the
native Americans and aborigines from Samoa.
Clinical features
The two most common presentations of psoriasis are
guttate (GP) and chronic plaque (CPP). The sexes are
equally affected in both types of psoriasis.
GP is characterised by a sudden eruption of small
red scaly papules on the trunk (GP comes from the
Greek word “guttata” meaning raindrop). The limbs
may also be involved. New lesions may continue to
appear for the ﬁrst month of the eruption, the lesions
remain for a second month and during the third
month, the GP lesions gradually fade. GP is most
commonly seen in children, adolescents and young
adults. In two-thirds of patients, there is evidence
of a preceding throat infection with b haemolytic
streptococci.
CPP usually presents between the ages of 15–30
years. The commonest sites are the extensor elbows,
knees and scalp. The onset is insidious and the plaques
are of varying size, i.e. 1–10cm. CPP varies with
the so-called activity of the disease; skin lesions may
resolve spontaneously, remain the same for years, or
gradually increase in size with new ones appearing,
which may eventually coalesce to involve all the skin.
In patients with stable CPP, acute GP ﬂares may
occur, i.e. small papules appear on the trunk and
limbs. In this situation, the GP lesions may resolve
after three months, but the plaques remain as before
the GP ﬂare.
Natural history
GPusuallyhasagoodprognosisandresolvesafterthree
months.Howeverinasmallnumberofpatients,theGP
lesions do not resolve but progress to CPP. In addition,
even in those patients with GP, there is a risk that these
patients will develop CPP in later life. CPP, however,
has a variable prognosis. In mild disease, in approxi-
mately 50% of patients, a spontaneous or therapy-
induced remission will occur. However, recurrence of
the disease is high. Permanent remission occurred in
only 17% of patients over a 20 year follow-up.
Histology
Psoriasis is characterised by thickening of the
epidermis, due to hyperplasia of the keratinocytes.
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loss of the granular layer and an abnormal stratum
corneum consisting of loosely packed keratin and
inﬁltration with neutrophils. There is elongation of the
basement membrane with down growth of the rete
ridges to accommodate the hyperplasia of the
epidermal cells. In the dermis, there is an increase in
size and tortuosity of the capillaries in the dermal
papillae and a lymphocytic inﬁltrate. Neutrophil
microabscesses may be seen in the upper epidermis.
Genetics
Family studies
It has been observed for many years that psoriasis
tends to run in families. Studies have suggested that
psoriasis is inherited as a Mendelian dominant with
incomplete penetrance of the gene(s). However,
others have interpreted the family studies over
generations to imply a recessive mode of inheritance
with 90% penetrance. More recent studies have now
suggested that psoriasis is a polygenic disorder. In
addition, environmental factors are also important in
the expression of the psoriasis and it is now considered
a complex multifactorial disease.
Census studies
There have been two large census studies in psoriasis,
one in the Faroe Isles in which 30,000 individualswere
examined (Lomholt 1963) and the other in central
Sweden in which 40,000 individuals were seen
(Hellgren 1967). In the latter, it was found that
6.4% of relatives of patients with psoriasis were
affected compared to 1.96% ofthe general population.
In the study of the closed community of the Faroe
Isles, 91% of patients with psoriasis had a family
history. Recent analysis of the data from these two
studies supports the current concept that psoriasis is a
multifactorial disorder and that monogenic types of
inheritance are now excluded.
Twin studies
These have strongly supported the role of inheritance
in psoriasis as the concordance for monozygotic twins
is 70% and dizygotic twins 14%. Twin studies have
also shown that the clinical type of psoriasis, age of
onset, course and severity are to a large extent
determined by genetic factors.
HLA
Class I HLA studies have shown association with B13,
B17, B37 and B57. However, the strongest association
has been shown with Cw6. The association with the B
antigens is considered to be due to linkage disequili-
brium with Cw6.
The highest incidence of Cw6 in psoriasis is in
Caucasians and the reported incidence varies from 36
to 84%, the average being 60 to 65%. The incidence in
Asians is considerably lower, having been reported
as 26% in a study in Japanese and 17% in Chinese.
However, the incidence of Cw6 is still raised in Asians,
as the incidence in a control population in Asians is
1–2% compared to 10–15% in Caucasians.
Clinical features of psoriasis show a relationship to
Cw6 in Caucasians. Cw6 is associated with early
onset, GP eruptions, increased severity and a positive
family history (Hensler and Christophers 1985;
Gudjonsson et al 2002). However, the association
with GP psoriasis is not absolute and this pattern of
the disease can occur in patients who are not Cw6-
positive (Fry et al. 2006).
Class II antigens, DR4 and DR7 have also shown an
association with psoriasis. The incidence for DR7 is
the highest and is approximately 60% in Caucasians
(control population, 9–10%). Recently, a negative
association was reported for DR15 (Baker et al 2003).
Patients expressing this HLA antigen had mild
disease, late onset and no GP eruptions.
Chromosome loci and genes
There are now seven loci reported for psoriasis,
PSORS1 on 6p21.3, PSORS2-17q25, PSORS3-
4q.34, PSORS4-1q21, PSORS5-3q, PSORS6-19p
and PSORS7-1p. These ﬁndings were described in
different ethnic groups and not all have been
conﬁrmed. The locus that has been found in most
studies is that on 6p21.3 and this region includes HLA
Cw6. However, as yet, no gene mutation has been
deﬁnitely identiﬁed on this locus using microsatellite
markers and single nucleotide polymorphisms
(SNPs). Some studies have implied that the poly-
morphism is within Cw6 itself, but most have reported
the region associated with psoriasis to be telomeric
to Cw6 and a few to be centromeric. Although
sequencing of Cw6 has shown an association between
alanine at position 73 and psoriasis in Japanese
patients, this was not been conﬁrmed in patients of
European extraction. Recently, gene mutations have
been reported in regions containing SLC9ARI on the
17q25 locus (Helms et al. 2003) and SLC12A8 on the
3q locus (Hewett et al. 2002). SLC9ARI is concerned
with transport of ions across cell membranes and
immune synapse formation in T cells and is adjacent
to a putative binding site for the transcription factor
RUNXI. It has also been proposed that Jun proteins,
the genes for which are located at the 19p locus, may
be implicated in psoriasis (Zenz et al. 2005).
Abrogation of Jun proteins has been shown to induce
the production of cytokines and chemokines, which
L. Fry et al. 362results in proliferation of keratinocytes and inﬁltration
of the epidermis with inﬂammatory cells.
Aetiology
Factors that may induce and/or aggravate psoriasis
include streptococcal infections, stress, trauma to the
skin (Koebner phenomenon), drugs, (particularly
lithium), alcohol, smoking, obesity and climate. Stress
and streptococcal infections have the most clear-cut
relationship to inducing or aggravating existing
psoriasis. In this article, the role of streptococcal
infections will be discussed in detail.
Streptococcal infections
It was noted over 50 years ago that an acute sore throat
often preceded the appearance of psoriasis (Norholm-
Pederson 1952). It was subsequently shown that in
patients with psoriasis, there was a signiﬁcantly higher
incidence of a positive streptococcal agglutination test
compared to patients with other skin diseases. The
associationofstreptococcalthroatinfectionswithGPis
much stronger than that with CPP. Either one or more
of the following is present in over half of patients with
GP: history of a sore throat approximately two weeks
prior to the eruption, a positive throat swab for b
haemolytic streptococci and a raised anti-streptolysin
titre. Conﬁrmation of a streptococcal infection in the
throat in GP is difﬁcult because the patients present a
fewweeksafter theinfectionwhentheorganismsareno
longer present on the surface of the tonsil. This may be
partly due to the ability of streptococci to penetrate
tonsillar epithelial cells where they may persist
indeﬁnitely, out of reach of the commonly used
antibiotic, penicillin. In addition, the anti-streptolysin
titre takes 10–14 days to appear in the blood and will
begintofallaftersixweekscontributingtothedifﬁculty
of conﬁrming that a streptococcal infection preceded
the initiation of skin lesions.
It has been shown that not only group A, b
haemolytic streptococci can trigger psoriasis but also
groups C and G (Belew et al. 1985). No particular
streptococcal serotype is linked to the induction of
psoriasis (Telfer et al. 1992).
There is evidence that CPP is also related to
streptococcal throat infections. First, it has been
reported that in patients with CPP recurrent sore,
throats are three times more common than in sex and
agematchedcontrols(Wardropetal.1998).Second,in
CPP b haemolytic streptococcal organisms (groups A,
C or G) are present in 20–30% of subjects (Cohen-
Tervaert and Esseveld 1970). Third, 25% of CPP
patients have raised anti-streptolysin titres (Cohen-
Tervaert and Esseveld 1970). The fact that evidence of
streptococcal organisms in the throat can be found for
only 25% of patients may suggest that streptococci are
more commonly located intracellularly in tonsils or
associated lymphoid tissue, where they could act as a
source of antigen to maintain the psoriatic process.
Immunology
Guttate psoriasis
The initiation of GP has been shown to be associated
with an inﬂux of activated CD4
þT lymphocytes into
the dermis and epidermis, whilst resolution is
associated with an inﬂux of activated CD8
þT cells
into the epidermis. In the initiation phase, activated
CD4
þT cells are in close apposition to the dendritic
processes of APCs, whilst in resolution, they are
replaced by activated CD8
þT cells. It is likely that the
hyperproliferation of the keratinocytes is induced by
cytokines secreted by activated CD4
þT cells; in
contrast, CD8
þT cells acting as regulatory cells
probably mediate resolution. In GP, it has been
shown that there is increased usage of TCR Vb2 and
Vb5.1 by inﬁltrating T cells suggestive of a super-
antigen effect (Lewis et al. 1993).
Chronic plaque psoriasis
In CPP, there is an inﬂux of activated CD4
þT cells in
the dermis and of both activated CD4
þ and CD8
þ
T cells in the epidermis. It had been assumed that the
CD4
þT cells were effector cells and that the CD8
þ
T cells acted as suppressor or regulatory cells.
However, recently it has been suggested that the
CD8
þT cells may have an effector role in CPP
(Gudjonsson et al. 2004). In CPP, oligoclonality of
inﬁltrating T cells has been demonstrated suggesting
that that they are activated by a speciﬁc antigen.
As aresult of the initial studies of T cells in psoriasis,
a hypothesis was put forward that “psoriasis is a
hyperproliferative disorder of keratinocytes mediated
by T lymphocytes” (Valdimarsson et al. 1986).
Nature of the antigen
Thus, it is accepted that the hyperproliferation of
the keratinocytes is due to cytokines produced by
activated T cells. What has still to be determined is the
nature of the antigen that activates the T cells.
In GP, the increased usage of particular Vb families
suggests a superantigen effect. Streptococcal organ-
isms produce a number of superantigens including
exotoxins A, C, F, X and SMP2. Analysis of the TCR
in GP psoriasis has revealed extensive region diversity
supporting the activation of T cells by superantigens
(Leung et al. 1995).
In CPP, there is oligoclonality of the TCR indicative
of a speciﬁc antigen. The candidates for a strepto-
coccal antigen include cellular proteins, such as Tand
M proteins, cell wall and cell membrane proteins.
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psoriasis lesions respond to whole streptococcal, cell
wall and cell membrane extracts (Baker et al. 2001;
Brown et al. 2001). The response is measured by
proliferation and/or IFN-g production. Peptidoglycan
is the major constituent of the cell wall; our group
therefore tested skin T cell responses to streptococcal
peptidoglycan (PG) and found speciﬁc HLA-DR
restricted responses to this antigen (Baker et al. 2006).
We have also recently shown that cells containing
peptidoglycan are signiﬁcantly increased in the dermis
of psoriatic lesions (Figures 1 and 2), and that a
proportion of these cells are macrophages (Baker et al.
2006). It is possible that if streptococcal organisms are
present and persist in the lymphoid tissue in the
throat, that peptidoglycan is released and taken up by
macrophages, which carry the bacterial antigen to
tissues including the skin (Figure 3). In addition,
T cells present in the tonsils would be primed to
streptococcal antigens including peptidoglycan and
induced to express the skin homing receptor,
cutaneous lymphocyte antigen (CLA), by interaction
with streptococcal toxins. These primed tonsillar
T cells would then be able to inﬁltrate the skin where
they could again encounter peptidoglycan. Activation
of T cells by peptidoglycan would result in the
production of cytokines, which in turn would induce
keratinocyte hyperproliferation.
Another theory proposed for psoriasis is that
streptococcal M protein induces the disease. It has
been suggested that M protein initiates the psoriatic
process and because of homology between M protein
Figure1. Macrophagescontaining PG in lesionalpsoriasitic skin. Increasednumber of 2E9-positivecells are presentin the upperdermisand
dermal papillae. E ¼ epidermis; D ¼ dermis; and 2E9 is a monoclonal antibody anti-PG IgG3 kindly supplied by Dr Jon Laman of Erasmus
Medical Centre, Rotterdam.
Figure 2. In comparison, normal skin showing very few positive 2E9 cells. E ¼ epidermis; and D ¼ Dermis
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epidermal antigen, which is up-regulated in the skin in
psoriasis (Sigmundsdottir et al. 1997; Gudmundsdot-
tir et al. 1999). In support of this autoimmune cross-
reactive hypothesis, circulating CLA
þ CD8
þT cells in
Cw6-positivepsoriasis patients were shownto respond
to a predicted Cw6-binding peptide from keratin 17
that shares the ALEEAN sequence with M protein
(Johnston et al. 2004). In contrast, a response to M
protein has not been detected for CD4
þT cell lines
cultured from psoriasis skin lesions (Baker et al. 2001;
Brown et al. 2001).
Psoriasis and Crohn’s disease
Patients with Crohn’s disease (CD) and their ﬁrst-
degree relatives, have a ﬁvefold increase in psoriasis
(Yatesetal.1982;Leeetal.1990).Thus,thereappears
to be a genetic link between the two diseases.
Interestingly both psoriasis and CD have susceptibility
loci on chromosomes 3, 4, 5 and 16 (Najarian and
Gottlieb 2003). In CD, a mutation has been found on
chromosome16q21inthegeneforNOD2(CARD15).
NOD2 is an innate immune receptor for muramyl
dipeptide (MDP) a constituent of peptidoglycan. It
has been found in CD that in patients with NOD2
mutations, there is an altered immunological response
to MDP; peripheral blood mononuclear cells show
decreased production of the pro-inﬂammatory cyto-
kines, TNF-a and 1L-1b. As a consequence, there is a
defective recruitment of neutrophils, which leads to
a decreased immune response to bacteria (Van Heel
et al. 2005). However in another recent study, it has
been shown, there is a weaker immune response to
bacterial extracts, compared to controls, which was
independent of NOD2 mutations (Marks et al. 2006).
It has been proposed that the defects in the innate
immunesysteminCDresultinfailureofearlyimmune
pathogen clearance and explains the abnormal adap-
tive immune response to microbial antigens.
Although theNOD2mutationshavenotbeenfound
in psoriasis (Borgiani et al 2002; Young et al. 2003),
mutations in other receptors in the innate immune
system may exist. Recently, four peptidoglycan
recognition proteins (Pglyrp) have been described,
the genes for three of which are at loci for psoriasis;
Pglyrp-2 is found on 19p13.12 (PSORS6) and Pglyrp-
3 and Pglyrp-4on 1q21 (PSORS4). A recent study has
shown a possible association of Pglyrp-3 and Pglyrp-4
with psoriasis in the transmission disequilibrium test
(TDT); however, this was not conﬁrmed in the case-
control test (Sun et al. 2006).
As yet, there is no evidence of impaired innate
immunity in psoriasis but only limited investigations
have been carried out. Because of the similarity
between CD and psoriasis, i.e. they are both chronic
inﬂammatory diseases and there is accumulating
evidence that both are induced by bacterial
components, it is possible that there is a defect in
the innate immune system in psoriasis. Furthermore,
bacterial peptidoglycan also appears to be a candidate
in psoriasis following the demonstration of an adaptive
T cell immune response to streptococcal PG in skin
lesions (Baker et al. 2006).
Figure 3. Possible pathway of streptococcal PG from the throat to the skin.
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There is now substantial evidence, both clinical and
laboratory based, that streptococci are involved in the
pathogenesis of psoriasis. Whether the primary site of
pathogenesis is in the lymphoid tissue in the throat,
or in the skin, has yet to be determined.
Streptococcal PG is a good candidate for an
aetiological factor in psoriasis as it has the ability to
affect both innate and adaptive immune responses.
As mentioned above, evidence already exists for an
adaptive immune response (Baker et al. 2006). If it is
accepted that streptococci are involved in the
pathogenesis of psoriasis, then vaccination may well
have a role to play in prevention and management of
the disease. However, it should be stressed that
streptococci may not be the only microorganisms
that induce or maintain the disease. Other possible
candidates include Staphylococcus aureus, Candida
albicans(Leunget al. 1993) andPityrosporum orbiculare
(Baker et al. 1997). The type of vaccines to be
developed for combating Streptococcus pyogenes in
psoriasiswillhavetobelefttovaccinologists.However,
it is pertinent that a vaccine against S. pneumoniae,
based on the cell wall (PG), already exists and has
shown to be effective (Prymula et al. 2006).
Psoriasis is considered to be a complex multi-
factorial disease and genetic defects involving clear-
ance of microorganisms and/or hyperproliferation of
keratinocytes may be involved. It is salutary to recall
that over 100 years ago, Radcliffe Cocker in his
Textbook of Dermatology stated that psoriasis was
due to bacteria on the skin. This may still prove to be
correct. Current treatments are focused on suppres-
sing the immune system; elimination of, or protection
from, bacteria by vaccination may represent a new and
possibly more effective treatment for this common
skin disease.
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